International Journal For Advanced Research In Science & Technology
A peer reviewed international journal
www.ijarst.in
ISSN: 2457-0362

A STUDY ON DRY POWDER WITH PRESCRIPTION DRUGS

Trupti Prakash Shinde, Dr. Nilesh M. Mahajan

DESIGNATION- RESEARCH SCHOLAR SUNRISE UNIVERSITY ALWAR
DESIGNATION = Professor SUNRISE UNIVERSITY ALWAR

ABSTRACT

Dry powder inhalers (DPIs) are an advanced method of delivering prescription medications for respiratory diseases. The complex systems that control DPIs are crucial in determining their effectiveness and therapeutic influence. Dry powder inhalers (DPIs) function by administering medicine in a powdered state straight to the respiratory system. This method has several benefits, such as improved drug durability and a decrease in overall negative effects. The process begins when the patient inhales via the DPI device, causing a reduction in air pressure within the inhaler. The decrease in pressure causes the scattering of finely divided drug particles from the device, therefore aiding their passage into the respiratory system. The size of these medication particles is a crucial determinant, often falling within the range of 1-5 micrometers, to ensure the most effective placement in the lower respiratory tract. The composition of the dry powder is similarly important, as it affects the efficiency of aerosolization and the overall performance of the medicine. Carrier particles, often consisting of lactose, play a crucial role in facilitating the dispersion of the active medication particles during inhalation. The selection of carrier material and its properties have a substantial influence on the efficacy of medication delivery.

KEYWORDS: Dry Powder, Prescription Drugs, DPI device, medication delivery, medication particles.

INTRODUCTION

In recent years, the field of respiratory medicine has witnessed remarkable advancements, particularly in the realm of inhalation therapy. Dry Powder Inhalers (DPIs) have emerged as pivotal devices in the administration of prescription drugs for respiratory conditions, revolutionizing the treatment landscape for patients with ailments such as asthma and chronic obstructive pulmonary disease (COPD). The intricate mechanisms underlying these inhalers play a crucial role in ensuring the effective delivery of prescribed medications to the respiratory system. This introduction aims to delve into the multifaceted world of DPIs,

elucidating their design principles, operational mechanisms, and the integration of prescription drugs into these inhalation devices. Dry Powder Inhalers represent a distinct category of inhalation devices that have gained widespread acceptance in clinical practice due to their user-friendly nature, portability, and efficient drug delivery. Unlike traditional metered-dose inhalers (MDIs) that rely on propellants, DPIs operate on the principle of delivering medication in a powdered form, making them an attractive option for patients and healthcare providers alike. The pharmaceutical industry's relentless pursuit of innovative drug delivery systems has led to the evolution of DPIs, each designed with precision to optimize drug dispersion and deposition in the lungs. The fundamental concept behind DPIs involves the delivery of dry powdered medication directly to the airways, where it can exert its therapeutic effects. This method not only eliminates the need for propellants but also enhances the stability of certain drugs, a critical consideration in the development of inhalation therapies. As we navigate through the intricacies of DPIs, it becomes evident that these devices comprise a myriad of components working harmoniously to facilitate the efficient and targeted delivery of prescription drugs.

A cornerstone of DPIs is their distinctive formulation of dry powder. The pharmaceutical industry employs various techniques to create fine particles that are conducive to optimal lung deposition. Techniques such as spray drying, micronization, and co-spray drying are employed to produce powders with particle sizes tailored to ensure deep penetration into the respiratory tract. The choice of excipients, carriers, and the drug itself plays a pivotal role in determining the aerosolization properties of the powder. This meticulous formulation process is a testament to the pharmaceutical industry's commitment to precision in designing DPIs that maximize therapeutic outcomes. The mechanical design of DPIs is equally critical in achieving efficient drug delivery. DPIs are broadly classified into two main categories based on their mechanical operation: single-dose and multi-dose inhalers. Single-dose DPIs are pre-loaded with a unitary dose of medication, whereas multi-dose DPIs allow for multiple administrations from a single device. The mechanical actuation of these devices, often driven by the patient's inhalation effort, is a key determinant in the dispersion of dry powder. Understanding the intricacies of these mechanical systems is imperative for healthcare providers and patients to ensure optimal drug delivery. The essential components of a DPI include the powder reservoir, the dose-metering mechanism, and the dispersion system. The powder reservoir serves as the repository for the powdered medication, while the dose-metering mechanism ensures accurate and reproducible dosing. The dispersion system,

comprising a combination of blisters, capsules, or rotating disks, facilitates the release and dispersion of the powdered medication upon inhalation. These components collectively contribute to the seamless functioning of DPIs, exemplifying the synergy between pharmaceutical science and engineering in the realm of respiratory medicine.

One of the distinctive features of DPIs is their reliance on the patient's inhalation effort for drug delivery. This breath-actuated mechanism obviates the need for propellants or external power sources, rendering DPIs highly portable and user-friendly. However, it also underscores the importance of patient education and training in ensuring the proper use of these devices. Healthcare providers play a pivotal role in empowering patients with the knowledge and skills necessary for effective DPI utilization. Techniques such as slow and steady inhalation, breath-holding, and proper device priming are essential elements of patient training programs, fostering optimal drug deposition and therapeutic outcomes. In the context of prescription drugs, DPIs have become indispensable in the management of respiratory conditions that demand targeted drug delivery to the lungs. Corticosteroids, bronchodilators, and combination therapies are among the prescription drugs commonly formulated for use with DPIs. The choice of drug and its formulation are intricately linked to the specific requirements of the respiratory condition being treated. For instance, the treatment of asthma often involves the use of inhaled corticosteroids to alleviate inflammation, while bronchodilators play a central role in the management of COPD. The integration of these prescription drugs into DPI formulations epitomizes the marriage of pharmaceutical science and clinical need, providing healthcare practitioners with a diverse arsenal of therapeutic options.

DRUG DELIVERY SYSTEMS

Drug delivery systems are crucial in pharmacology since they provide creative methods to improve the effectiveness, safety, and patient adherence of pharmacological medicines. These systems include the deliberate administration, focusing, and confinement of medications, with the objective of enhancing their distribution and effects inside the body. Medication delivery systems use several formulations and technology to address issues such as medication solubility, stability, and bioavailability. This extensive investigation encompasses a wide range of medication delivery strategies, including conventional oral formulations as well as cutting-edge Nano carriers and implanted devices.

1. **Oral Drug Delivery:** Oral drug delivery continues to be a widely used and convenient method of administering medication. Conventional oral formulations include pills, capsules, and syrups. These formulations provide benefits such as simplicity in use, adherence by patients, and cost-efficiency. Modified-release formulations, such as extended-release tablets or capsules, provide the medicine gradually and consistently over a long period of time, reducing the frequency of dose. Oral drug delivery research also focuses on enhancing the bioavailability of medications that have low solubility. This is achieved by using methods including nanoparticle formulation, cyclodextrins complexation, and lipid-based delivery systems.

2. **Transdermal Drug Delivery:** Transdermal drug delivery systems provide medications via permeating the skin in order to produce widespread effects throughout the body. Transdermal patches are specifically formulated to gradually release medication over a long duration, providing benefits such as less adverse reactions, enhanced patient adherence, and avoidance of initial metabolism in the liver. The skin's barrier qualities provide difficulties, and methods to improve drug penetration include the use of permeation enhancers, prodrugs, and innovative delivery systems. Transdermal systems are especially beneficial for medications that need a consistent and prolonged delivery, such as those used in pain treatment or hormone replacement therapy.

3. **Injectable Drug Delivery:** Injectable drug delivery systems provide a direct pathway for administering medications into the circulation, guaranteeing quick onset of effects and optimal drug absorption. Common routes of delivery include intravenous (IV), intramuscular (IM), and subcutaneous (SC) injections. Injectable formulations have made significant progress with the introduction of biodegradable microspheres and nanoparticles, which enable controlled and precise release of drugs. The parenteral route is essential for some medications that exhibit poor oral absorption or need quick therapeutic effects.

4. **Inhaled Drug Delivery:** Inhaled medication delivery is used for the management of respiratory ailments such as asthma and chronic obstructive pulmonary disease (COPD). The types of inhalation systems are metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. These devices provide medications directly

to the lungs, resulting in a quick start of effects and reducing the occurrence of adverse effects throughout the body. Inhalation formulations often use micronized particles to achieve optimum lung deposition. The field of inhaled medicine administration is constantly advancing with the creation of intelligent inhalers that integrate sensors and connections to monitor patient compliance and treat diseases.

5. **Nano particulate Drug Delivery:** Nano particulate drug delivery methods use nanoscale carriers to augment medication solubility, stability, and bioavailability. Nanoparticles, liposomes, and micelles are some of the nanocarriers used. These methods provide precise administration of medication, especially to affected areas, and may enhance the absorption by cells. Furthermore, Nano particulate systems aid in addressing difficulties related to medications with low solubility. Nanoparticles may be modified on their surface with ligands, which enables precise targeting and leads to less side effects and improved therapeutic results.

PULMONARY DRUG ABSORPTION

Pulmonary drug absorption is the mechanism via which medications are assimilated into the circulatory system after administration via the lungs. The pulmonary route of drug administration has become important because of the distinctive features of the respiratory system, including benefits such as quick absorption, bypassing the liver's first processing, and a substantial surface area for drug absorption. The primary modalities for administering medications to the respiratory system include the inhalation of aerosols, dry powder inhalers, and nebulizers.

Drug particles are delivered to the alveoli, which are small air sacs in the lungs responsible for gas exchange, when they are inhaled. The alveolar epithelium, consisting of a thin layer of cells, offers a substantial surface area and a relatively little distance for medicines to diffuse into the circulation. The main determinants affecting the absorption of drugs in the lungs are the physicochemical characteristics of the medication, the size of the particles, and the breathing rhythm of the person.

The respiratory epithelium exhibits permeability to a wide range of pharmacological compounds, facilitating both passive and active transport processes. Lipophilic medications have enhanced diffusion across cell membranes that are rich in lipids, while hydrophilic drugs may depend on specialized transporters. The alveolar epithelium is

equipped with tight connections, which restrict par acellular transit and need medications to pass through the epithelial cells.

The size of particles is essential in the absorption of drugs in the lungs. Smaller particles are more likely to reach the alveoli, where absorption takes place, while bigger particles may settle in the upper airways and be removed by mucociliary action or coughing. The ideal particle size for effective absorption generally ranges from 1 to 5 micrometers.

The pulmonary blood flow also enhances the process of medication absorption. Upon absorption into the alveolar capillaries, medicines are swiftly conveyed to the systemic circulation, bypassing the hepatic first-pass impact. As a consequence, pulmonary drug administration is highly appropriate for medications that need prompt therapeutic effects due to its fast commencement of action.

Pulmonary drug absorption refers to the process by which pharmaceuticals are taken up via the pulmonary epithelium following inhalation. The effectiveness of absorption is influenced by several variables, including drug characteristics, particle size, and breathing patterns. This method of delivery is extensively used because to its quick initiation of effects and the ability to bypass liver metabolism, which is crucial in the creation of different pharmacological formulations.

MECHANICS OF DRY POWDER INHALERS

Dry powder inhalers (DPIs) are specifically engineered devices used to administer drugs directly to the lungs in the form of dry powder. They have a vital function in the management of respiratory ailments including asthma and chronic obstructive pulmonary disease (COPD). To comprehend the mechanics of DPIs, one must thoroughly investigate their design, operational principles, and important factors to consider.

The core component of a DPI is the drug formulation, which usually comprises of micronized drug particles mixed with carriers. These carriers aid in the distribution of the medicine when inhaled and assist in preserving the powder's stability. The selection of carriers, such as lactose or mannitol, is crucial in determining the efficacy of the DPI.

Breath-actuation is one of the main methods used by DPIs to function. DPIs are inhalation devices that are activated by the patient's breath, causing the medicine to be

released. This design has several benefits, such as enhanced medication administration efficiency and less reliance on the patient's coordination abilities. During inhalation, the airflow creates a region of reduced pressure inside the DPI, causing the powder to be drawn out of the device and into the flow of air.

The distribution of powder particles in dry powder inhalers (DPIs) is affected by several parameters, with particle size being a crucial element. The particle size distribution of the medicine has a direct influence on the aerodynamic properties of the powder, which in turn affects its capacity to reach the lower respiratory regions where absorption takes place. Manufacturers meticulously design the distribution of particle sizes to enhance the deposition of particles in the lungs and maximize the effectiveness of the therapy.

The formulation is contained in a reservoir located inside the DPI. The design of this reservoir is essential to guarantee the accurate measurement and even distribution of the powder. A prevalent design is the blister or capsule-based reservoir, in which different dosages are enclosed in distinct compartments. When you breathe in, a blister or capsule is perforated, causing the powder to be released for inhalation. This construction not only protects the powder from environmental elements but also guarantees uniform dosing.

The breath-actuation mechanism of the device is often performed using many methods, including mechanical, adhesive, or elastic forces. Mechanical DPIs use a trigger mechanism that is actuated by the patient's inhaling exertion. This may include the use of a lever, button, or other mechanical elements that dispense the powder upon activation. Adhesive dry powder inhalers (DPIs) use the adhesive characteristics of certain materials to retain the powder in position until the airflow generated during inhalation surpasses the adhesive forces, hence enabling the release of the powder. Elastic DPIs use the elastic characteristics of materials, such as springs or elastic bands, to accumulate energy during the loading phase and then release it after inhalation in order to distribute the powder.

CONCLUSION

The study on the mechanisms of dry powder inhalers (DPIs) with prescription drugs is essential to address critical gaps in our understanding of the delivery and efficacy of medications for respiratory conditions. DPIs have become increasingly prevalent in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease

(COPD). However, despite their widespread use, there is a need to delve deeper into the intricate mechanisms governing the dispersion and deposition of prescription drugs within the respiratory system. Understanding the nuances of DPI mechanisms is crucial for optimizing drug delivery efficiency and ensuring that patients receive the prescribed dosage effectively. Factors such as powder formulation, inhaler design, and patient technique can significantly impact drug deposition in the lungs. Therefore, a comprehensive study will contribute valuable insights into the interplay between these factors, enabling the refinement of DPI technology for enhanced therapeutic outcomes.

REFERENCES

1. Adi S, Tong Z, Chan HK, Yang R, Yu A. Impact angles as an alternative way to improve aerosolisation of powders for inhalation?. Eur J Pharm Sci. 41 (2010) 320-327.

2. Agrawal, Gauravkumar & Wakte, Pravin & Shelke, Santosh. (2017). Formulation, physicochemical characterization and in vitro evaluation of human insulin-loaded microspheres as potential oral carrier. Progress in Biomaterials. 6. 10.1007/s40204-017-0072-z.

3. Altay Benetti, Ayça & Bianchera, Annalisa & Buttini, Francesca & Bertocchi, Laura & Bettini, Ruggero. (2021). Mannitol Polymorphs as Carrier in DPIs Formulations: Isolation Characterization and Performance. Pharmaceutics. 13. 1113. 10.3390/pharmaceutics13081113.

4. Aquino, Rita & Auriemma, Giulia & Conte, Giulio & Esposito, Tiziana & Sommella, Eduardo & Campiglia, Pietro & Sansone, Francesca. (2020). Development of Chitosan/Mannitol Microparticles as Delivery System for the Oral Administration of a Spirulina Bioactive Peptide Extract. Molecules. 25. 2086. 10.3390/molecules25092086.

5. Ari A. Jet, Ultrasonic, and Mesh Nebulizers: An Evaluation of Nebulizers for Better Clinical Outcomes. Eurasian J Pulmonol. 2014;16(1):1-7.

6. Biddiscombe MF, Barnes PJ, Usmani OS. A Short PDI Can Be a Reliable Test of Lung Function in Patients with Obstructive Airway Disease. Respir Med. 2011;105(5):730-738.

7. Borgström L, Asking L, Lipniunas P. Pharmacokinetics of Inhaled Dry Powder Drugs. Clin Pharmacokinet. 2006;45(12):1105-1118.

8. Bruni, Giovanna & Berbenni, Vittorio & Milanese, Chiara & Girella, A. & Cofrancesco, Pacifico & Bellazzi, G. & Marini, Amedeo. (2009). Physicochemical characterization of anhydrous D -mannitol. Journal of Thermal Analysis and Calorimetry - J THERM ANAL CALORIM. 95. 871-876. 10.1007/s10973-008-9384-5.

9. Chougule, Mahavir & Padhi, Bijay & Jinturkar, Kaustubh & Misra, Ambikanandan. (2007). Development of Dry Powder Inhalers. Recent patents on drug delivery & formulation. 1. 11-21. 10.2174/187221107779814159.

10. Cipolla D, Gonda I. Comparison of Particle Size Distribution of Valved Holding Chamber and Nebulizer Output. Respir Care. 2016;61(8):1084-1090.

11. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers--implications for in vitro testing. J Aerosol Med. 1993;6(2):99-110.